Ajanta Pharma Reports 20% Revenue Growth & 18% PAT Growth in Q3 FY 2026

Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, reported its excellent performance for the quarter and nine months ended 31st December 2025. Q3 FY 2026 performance highlights: Revenue from operations at Rs. 1,375 cr. against Rs. 1,146 cr.; up 20%. EBITDA at Rs. 382 cr. against Rs. 321 cr.; up 19%. Profit after tax at Rs. 274 cr. against Rs. 233 cr.; PAT at 20%; up 18%. 9M FY 2026 performance highlights: Revenue from operations at Rs. 4,031 cr. against Rs. 3,478 cr.; up 16%. EBITDA at Rs. 1,061 cr. against Rs. 962 cr.; up 10%. Profit after tax at Rs. 789 cr. against Rs. 695 cr.; PAT at 20%; up 14%. ROCE stood at a healthy level of 34% and RONW at 26%.